<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008734</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002967-24</org_study_id>
    <secondary_id>2013/2016</secondary_id>
    <nct_id>NCT02008734</nct_id>
  </id_info>
  <brief_title>Randomized Phase II Study to Assess PD 0332991 in Breast Cancer</brief_title>
  <acronym>POP</acronym>
  <official_title>Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in Early Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II study trying to identify whether short term treatment with PD0332991&#xD;
      yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at&#xD;
      surgery- or induces senescence as determined by SABG expression (IHC) in tumors from patients&#xD;
      with early breast cancer non-candidates for neoadjuvant hormonotherapy or chemotherapy, as&#xD;
      compared to no treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti proliferative response</measure>
    <time_frame>Assessed at Day 15 after randomization</time_frame>
    <description>percentage of patients who at Day 15 have a natural logarithm of percentage positive IHC staining Ki67 of &lt;1 for each study drug (Ki67 &quot;absolute&quot; antiproliferative responders).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Assessed at Day 8 and 15 after randomization</time_frame>
    <description>Using NCI CTCAE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ki67</measure>
    <time_frame>Assessed at Day15 after randomization</time_frame>
    <description>Relative change from baseline to surgery in Ki67 IHC expression (&quot;relative&quot; antripoliferative responders)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Untreated Operable Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD0332991</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD0332991</intervention_name>
    <arm_group_label>PD0332991</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Female patients aged 18 years or older.&#xD;
&#xD;
          3. Histologically or cytologically confirmed untreated invasive carcinoma of the breast&#xD;
             irrespective of HER2 and ER status&#xD;
&#xD;
          4. No personal history of breast cancer within the last 5 years&#xD;
&#xD;
          5. Candidates for initial breast surgery, with a minimum size of 15 mm measured by breast&#xD;
             US. Bilateral and multifocal tumors are allowed, assuming tumor evaluations and pre-&#xD;
             and post-treatment biopsies are performed in the same target lesion.&#xD;
&#xD;
        7. High proliferative tumor as defined by either Grade 3 or Ki67 ≥20% 8. No evidence of&#xD;
        metastatic disease. 9. Eastern Cooperative Oncology Group (ECOG) performance status 0/1.&#xD;
        10. Left ventricular ejection fraction (LVEF) of at least 50% 11. Negative pregnancy test&#xD;
        in women of childbearing potential within 14 days prior to treatment initiation&#xD;
        (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not&#xD;
        undergone surgical sterilization).&#xD;
&#xD;
        12. For women of childbearing potential who are sexually active, agreement to use a highly&#xD;
        effective, non-hormonal form of contraception or two effective forms of non-hormonal&#xD;
        contraception during and for at least 6 months post-treatment.&#xD;
&#xD;
        13. Patients must be affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients non-candidate for upfront breast surgery or candidate for neoadjuvant&#xD;
             chemotherapy or hormonotherapy.&#xD;
&#xD;
          2. Patients with previously treated breast cancer during the last 5 years or receiving&#xD;
             another concomitant anticancer treatment like chemotherapy, immunotherapy, endocrine&#xD;
&#xD;
        4. Known hypersensibility to PD0332991 or any of its components. 5. Difficulty to swallow&#xD;
        oral medication 6. Serious uncontrolled concomitant disease that would put the patient at&#xD;
        high risk for treatment-related complications.&#xD;
&#xD;
        7. Patient whose general clinical condition does not consider postponing surgery 8.&#xD;
        Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
          -  Absolute neutrophil count &lt;1,500 cells/mm3&#xD;
&#xD;
          -  Platelet count &lt;100,000 cells/mm3&#xD;
&#xD;
          -  Hemoglobin &lt;9 g/dL&#xD;
&#xD;
          -  Total bilirubin greater than 1,5 times the upper limit of normal (ULN) (unless the&#xD;
             patient has documented Gilbert's syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) &gt;2.5&#xD;
             x ULN&#xD;
&#xD;
          -  Serum creatinine &gt;2.0 mg/dL and/or 177 μmol/L clearance creatinine &lt;50mL/min&#xD;
             (calculated by Cockcroft-Gault method)&#xD;
&#xD;
          -  International normalized ratio (INR) and activated partial thromboplastin time (aPTT)&#xD;
             or partial thromboplastin time (PTT) &gt;1.5 x ULN (unless on therapeutic coagulation) 9.&#xD;
             Uncontrolled hypertension (systolic &gt;150 mmHg and/or diastolic &gt; 100 mmHg) or&#xD;
             clinically significant (i.e. active) cardiovascular disease: cerebrovascular&#xD;
             accident/stroke or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or&#xD;
             higher; or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
             10. Patients with a history of long-QT syndrome or documented family history of&#xD;
             long-QT syndrome.&#xD;
&#xD;
             11. QTc &gt;470 12. serum potassium level &lt; LLN 13. Uncontrolled intercurrent illness&#xD;
             including but not limited to, known active infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B or C virus or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
             14. Assessed by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
             15. Pregnant or breastfeeding patients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Arnedos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gustaveroussy.fr/fr/essai/cancers-du-sein-cancer-9</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

